{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T05:37:27Z","timestamp":1740202647951,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s12325-010-0035-4","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T16:55:36Z","timestamp":1276016136000},"page":"307-313","source":"Crossref","is-referenced-by-count":10,"title":["Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia"],"prefix":"10.1007","volume":"27","author":[{"given":"Tomiki","family":"Sumiyoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Kurachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,8]]},"reference":[{"key":"35_CR1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","volume":"26","author":"M.F. Green","year":"2000","unstructured":"Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the \u201cright stuff\u201d? Schizophr Bull. 2000;26:119\u2013136.","journal-title":"Schizophr Bull."},{"key":"35_CR2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0920-9964(99)00198-X","volume":"45","author":"S.R. McGurk","year":"2000","unstructured":"McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res. 2000;45:175\u2013184.","journal-title":"Schizophr Res."},{"key":"35_CR3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.06.008","volume":"95","author":"T. Sumiyoshi","year":"2007","unstructured":"Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007;95:158\u2013168.","journal-title":"Schizophr Res."},{"key":"35_CR4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","volume":"295","author":"M.J. Millan","year":"2000","unstructured":"Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000;295:853\u2013861.","journal-title":"J Pharmacol Exp Ther."},{"key":"35_CR5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","volume":"15","author":"R.A. Bantick","year":"2001","unstructured":"Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol. 2001;15:37\u201346.","journal-title":"J Psychopharmacol."},{"key":"35_CR6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","volume":"195","author":"H.Y. Meltzer","year":"2008","unstructured":"Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res. 2008;195:98\u2013102.","journal-title":"Behav Brain Res."},{"key":"35_CR7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s12325-008-0102-2","volume":"25","author":"T. Sumiyoshi","year":"2008","unstructured":"Sumiyoshi T, Bubenikova-Valesova V, Horacek J, Bert B. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther. 2008;25:1037\u20131056.","journal-title":"Adv Ther."},{"key":"35_CR8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1017\/S1461145704004845","volume":"7","author":"K.P. Lesch","year":"2004","unstructured":"Lesch KP, Gutknecht L. Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int J Neuropsychopharmacol. 2004;7:381\u2013385.","journal-title":"Int J Neuropsychopharmacol."},{"key":"35_CR9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1017\/S1461145707008218","volume":"11","author":"A. Drago","year":"2008","unstructured":"Drago A, Ronchi DD, Serretti A. 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int J Neuropsychopharmacol. 2008;11:701\u2013721.","journal-title":"Int J Neuropsychopharmacol."},{"key":"35_CR10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0024-3205(91)90556-Q","volume":"48","author":"T. Hashimoto","year":"1991","unstructured":"Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 1991;48:355\u2013363.","journal-title":"Life Sci."},{"key":"35_CR11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0006-8993(95)01361-X","volume":"708","author":"T. Sumiyoshi","year":"1996","unstructured":"Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 1996;708:209\u2013214.","journal-title":"Brain Res."},{"key":"35_CR12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/15622970209150614","volume":"3","author":"S. Kasper","year":"2002","unstructured":"Kasper S, Tauscher J, Willeit M, et al. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette\u2019s disorder\u2014implications for psychopharmacology. World J Biol Psychiatry. 2002;3:133\u2013146.","journal-title":"World J Biol Psychiatry"},{"key":"35_CR13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archpsyc.59.6.514","volume":"59","author":"J. Tauscher","year":"2002","unstructured":"Tauscher J, Kapur S, Verhoeff NP, et al. Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry. 2002;59:514\u2013520.","journal-title":"Arch Gen Psychiatry"},{"key":"35_CR14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-006-0543-8","volume":"189","author":"W.G. Frankle","year":"2006","unstructured":"Frankle WG, Lombardo I, Kegeles LS, et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology (Berl). 2006;189:155\u2013164.","journal-title":"Psychopharmacology (Berl)."},{"key":"35_CR15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0006-3223(01)01202-1","volume":"50","author":"M.A. Lee","year":"2001","unstructured":"Lee MA, Meltzer HY. 5-HT(1A) receptor dysfunction in female patients with schizophrenia. Biol Psychiatry. 2001;50:758\u2013766.","journal-title":"Biol Psychiatry"},{"key":"35_CR16","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1176\/appi.ajp.161.8.1505","volume":"161","author":"T. Sumiyoshi","year":"2004","unstructured":"Sumiyoshi T, Meltzer HY. Serotonin1A receptors in memory function. Am J Psychiatry. 2004;161:1505.","journal-title":"Am J Psychiatry"},{"key":"35_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbr.2008.06.011","volume":"195","author":"J. Borg","year":"2008","unstructured":"Borg J. Molecular imaging of the 5-HT(1A) receptor in relation to human cognition. Behav Brain Res. 2008;195:103\u2013111.","journal-title":"Behav Brain Res."},{"key":"35_CR18","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1176\/appi.ajp.158.10.1722","volume":"158","author":"T. Sumiyoshi","year":"2001","unstructured":"Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001;158:1722\u20131725.","journal-title":"Am J Psychiatry"},{"key":"35_CR19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00004714-200006000-00019","volume":"20","author":"T. Sumiyoshi","year":"2000","unstructured":"Sumiyoshi T, Matsui M, Yamashita I, et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol. 2000;20:386\u2013388.","journal-title":"J Clin Psychopharmacol."},{"key":"35_CR20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11065-009-9103-4","volume":"19","author":"P.D. Harvey","year":"2009","unstructured":"Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev. 2009;19:324\u2013335.","journal-title":"Neuropsychol Rev."},{"key":"35_CR21","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.159.9.1593","volume":"159","author":"H.Y. Lane","year":"2002","unstructured":"Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry. 2002;159:1593\u20131595.","journal-title":"Am J Psychiatry"},{"key":"35_CR22","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1176\/ajp.2006.163.10.1826","volume":"163","author":"G.P. Reynolds","year":"2006","unstructured":"Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry. 2006;163:1826\u20131829.","journal-title":"Am J Psychiatry"},{"key":"35_CR23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.euroneuro.2004.07.001","volume":"15","author":"G.P. Reynolds","year":"2005","unstructured":"Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z. Pharmacogenetics of treatment in firstepisode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol. 2005;15:143\u2013151.","journal-title":"Eur Neuropsychopharmacol."},{"key":"35_CR24","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","volume":"32","author":"N.M. Richtand","year":"2007","unstructured":"Richtand NM, Welge JA, Logue AD, Keck PE, Jr., Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacol. 2007;32:1715\u20131726.","journal-title":"Neuropsychopharmacol."},{"key":"35_CR25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/0269881107081522","volume":"22","author":"L. Wang","year":"2008","unstructured":"Wang L, Fang C, Zhang A, et al. The \u20141019 C\/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol. 2008;22:904\u2013909.","journal-title":"J Psychopharmacol."},{"key":"35_CR26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1017\/S1461145704004663","volume":"7","author":"Y.Y. Huang","year":"2004","unstructured":"Huang YY, Battistuzzi C, Oquendo MA, et al. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol. 2004;7:441\u2013451.","journal-title":"Int J Neuropsychopharmacol."},{"key":"35_CR27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.neuropharm.2009.09.006","volume":"58","author":"T. Kishi","year":"2010","unstructured":"Kishi T, Tsunoka T, Ikeda M, et al. Serotonin1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacol. 2010;58:452\u2013456.","journal-title":"Neuropharmacol."},{"key":"35_CR28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1017\/S1461145704004687","volume":"7","author":"A. Serretti","year":"2004","unstructured":"Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol. 2004;7:453\u2013460.","journal-title":"Int J Neuropsychopharmacol."},{"key":"35_CR29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145704004699","volume":"7","author":"S. Lemonde","year":"2004","unstructured":"Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol. 2004;7:501\u2013506.","journal-title":"Int J Neuropsychopharmacol."},{"key":"35_CR30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.tpj.6500340","volume":"6","author":"C.J. Hong","year":"2006","unstructured":"Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006;6:27\u201333.","journal-title":"Pharmacogenomics J."},{"key":"35_CR31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.euroneuro.2005.12.004","volume":"16","author":"Y.W. Yu","year":"2006","unstructured":"Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. Association study of two serotonin1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol. 2006;16:498\u2013503.","journal-title":"Eur Neuropsychopharmacol."},{"key":"35_CR32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neulet.2008.03.001","volume":"436","author":"B.T. Baune","year":"2008","unstructured":"Baune BT, Hohoff C, Roehrs T, Deckert J, Arolt V, Domschke K. Serotonin receptor 1A-1019C\/G variant: impact on antidepressant pharmacoresponse in melancholic depression? Neurosci Lett. 2008;436:111\u2013115.","journal-title":"Neurosci Lett."},{"key":"35_CR33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2004.07.009","volume":"1023","author":"Y.C. Chung","year":"2004","unstructured":"Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res. 2004;1023:54\u201363.","journal-title":"Brain Res."},{"key":"35_CR34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejphar.2006.12.007","volume":"559","author":"M. Sato","year":"2007","unstructured":"Sato M, Ago Y, Koda K, et al. Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. Eur J Pharmacol. 2007;559:155\u2013160.","journal-title":"Eur J Pharmacol."},{"key":"35_CR35","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","volume":"76","author":"J. Ichikawa","year":"2001","unstructured":"Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O\u2019Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5- HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521\u20131531.","journal-title":"J Neurochem."},{"key":"35_CR36","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","volume":"25","author":"L. Diaz-Mataix","year":"2005","unstructured":"Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci. 2005;25:10831\u201310843.","journal-title":"J Neurosci."},{"key":"35_CR37","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association.","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (Text Revision). Washington DC: APA; 2000.","edition":"4th Edition"},{"key":"35_CR38","volume-title":"Structured Clinical Interview for DSM-IV Axis I Disorders","author":"M.B. First","year":"1997","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. New York: New York State Psychiatric Institute; 1997."},{"key":"35_CR39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.schres.2008.01.020","volume":"101","author":"Y. Higuchi","year":"2008","unstructured":"Higuchi Y, Sumiyoshi T, Kawasaki Y, Matsui M, Arai H, Kurachi M. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: A LORETA analysis of P300. Schizophr Res. 2008;101:320\u2013330.","journal-title":"Schizophr Res."},{"key":"35_CR40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.pscychresns.2008.07.005","volume":"172","author":"T. Sumiyoshi","year":"2009","unstructured":"Sumiyoshi T, Higuchi Y, Itoh T, et al. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA. Psychiatry Res Neuroimag 2009;172:180\u2013183.","journal-title":"Psychiatry Res Neuroimag"},{"key":"35_CR41","volume-title":"Scale for the Assessment of Positive Symptoms (SAPS)","author":"N.C. Andreasen","year":"1983","unstructured":"Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa; 1983."},{"key":"35_CR42","volume-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"N.C. Andreasen","year":"1983","unstructured":"Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1983."},{"key":"35_CR43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopsych.2005.06.016","volume":"59","author":"R.V. Parsey","year":"2006","unstructured":"Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59:106\u2013113.","journal-title":"Biol Psychiatry"},{"key":"35_CR44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/BF02281871","volume":"97","author":"J. Erdmann","year":"1996","unstructured":"Erdmann J, Shimron-Abarbanell D, Rietschel M, et al. Systematic screening for mutations in the human serotonin-2A receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet. 1996;97:614\u2013619.","journal-title":"Hum Genet."},{"key":"35_CR45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1586\/17512433.1.6.791","volume":"1","author":"T. Sumiyoshi","year":"2008","unstructured":"Sumiyoshi T. A possible dose-side effect relationship of antipsychotic drugs: Relevance to cognitive function in schizophrenia. Expert Rev Clin Pharmacol. 2008;1:791\u2013802.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"35_CR46","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0006-3223(00)01025-8","volume":"49","author":"T. Sumiyoshi","year":"2001","unstructured":"Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol Psychiatry. 2001;49:861\u2013868.","journal-title":"Biol Psychiatry"},{"key":"35_CR47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neulet.2004.03.079","volume":"24","author":"T. Yoshino","year":"2004","unstructured":"Yoshino T, Nishijima K, Shioda K, Yui K, Katoh S. Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medical prefrontal cortex. Neurosci Lett. 2004;24:16\u201321.","journal-title":"Neurosci Lett."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-010-0035-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0035-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:38:25Z","timestamp":1740166705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-010-0035-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1007\/s12325-010-0035-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}